Bamlanivimab

Carterra Expands Best-in-Class Franchise With the Launch of the LSAXT High-Throughput SPR Biosensor at SLAS 2023

Retrieved on: 
월요일, 2월 27, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, DEL, Society, Therapy, Atomic mass, CDC, Bamlanivimab, AbCellera, Exhibition, Cell, Software, Risk, Drug discovery, Kinetics, Marketing, Eli Lilly, SPR, COVID-19, ChromeOS, FC, ADCP, Inc., Science, Laboratory automation, Conference, SLAS, Antibody, Membrane, Cytokine, ADCC, LSA, Fine chemical, Pharmaceutical industry, Nature

Carterra will be showcasing the new LSAXT platform for high-throughput SPR at the SLAS event (booth 2127) with a launch program that includes a user presentation by Dragonfly Therapeutics on February 27 at 2:00 pm.

Key Points: 
  • Carterra will be showcasing the new LSAXT platform for high-throughput SPR at the SLAS event (booth 2127) with a launch program that includes a user presentation by Dragonfly Therapeutics on February 27 at 2:00 pm.
  • Speaking about the launch of the LSAXT at SLAS 2023, Christopher Silva, Vice President of Marketing and Product at Carterra added, “This is a great day for biologics discovery scientists and for Carterra.
  • You always run the risk of missed expectations when you launch a follow-on product after a game changer like the LSA.
  • But we’ve proved that with the LSAXT the story only gets better for us and our customers.”

AbCellera Reports Full Year 2022 Business Results

Retrieved on: 
화요일, 2월 21, 2023
Biotechnology, Pharmaceutical, Health, General Administration of Sport of China, Bamlanivimab, AbCellera, Partnership, Research, Webcast, S&M, Research and development, Investment, Bebtelovimab, R, Growth, Sales & Marketing Executives International, EUA, Administration, COVID-19, G&A, Video game, Reinsurance, Pharmaceutical industry

AbCellera started discovery on 23 partnered programs in 2022 to reach a cumulative total of 101 partnered program starts (up 29% from 78 on December 31, 2021).

Key Points: 
  • AbCellera started discovery on 23 partnered programs in 2022 to reach a cumulative total of 101 partnered program starts (up 29% from 78 on December 31, 2021).
  • AbCellera’s partners advanced an additional three molecules into the clinic in 2022, bringing the cumulative total to eight molecules in the clinic.
  • Revenue for the fourth quarter of 2022 was $21.5 million, representing 4% of the total for 2022.
  • AbCellera will host a conference call and live webcast to discuss these results today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time).

Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed/Refractory Lymphomas at 64th ASH Annual Meeting

Retrieved on: 
토요일, 12월 10, 2022
Neoplasm, SD, Marketing, ASH, DCR, B-cell lymphoma, American Society of Clinical Oncology, Research, Junshi, COVID-19, Lilly, NMPA, Clinical trial, Oncology, FDA, Lymphoma, Safety, Bamlanivimab, Cancer, PD-1, Social responsibility, Immunoglobulin superfamily, Dor, DLT, Society, CD28, Hodgkin lymphoma, HL, ASCO, TNF, ORR, Bamlanivimab/etesevimab, Ira Pastan, NHL, SSE, Development, Patient, Time-invariant system, HVEM, Poster, Microbiology, BTLA, EUA, HKEX, Lymphocyte, Infection, Autoimmunity, Severe acute respiratory syndrome coronavirus 2, Pharmaceutical industry, Vaccine, Medical imaging, Science, Chinese, Hematology

SHANGHAI, China, Dec. 10, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the updated preliminary data from a Phase I study of tifcemalimab as a single agent or in combination with toripalimab in relapsed/refractory lymphomas in a poster at the 64th American Society of Hematology (ASH) Annual Meeting. Tifcemalimab is the world’s first-in-human anti-tumor anti-BTLA monoclonal antibody independently developed by the company.

Key Points: 
  • The observed clinical activity of tifcemalimab in combination with toripalimab in lymphoma patients refractory to checkpoint inhibitors warrants further evaluation.
  • “However, if PD-1 inhibitors fail, there is no standard treatment to resort to, thus new treatment methods are urgently needed in clinical practice.
  • This is the very first time an anti-BTLA antibody was evaluated for safety and efficacy in the treatment of lymphomas.
  • Now, updated results from the clinical trial for lymphomas have been presented at the ASH annual meeting.

Junshi Biosciences Announces Approval of Supplemental Application for Additional Indications of Adalimumab Injection

Retrieved on: 
화요일, 11월 22, 2022
Autoimmunity, Marketing, Bamlanivimab/etesevimab, Macular edema, EUA, Rheumatism, Severe acute respiratory syndrome coronavirus 2, NMPA, Junshi, B cell, Inflammatory bowel disease, Incidence, TNF, Prevalence, Microbiology, Patient, IBD, Rheumatoid arthritis, HKEX, Ulcerative colitis, Cataract, UC, FDA, Multifocal choroiditis and panuveitis, COVID-19, Adalimumab, SSE, Glaucoma, Cancer, Ankylosing spondylitis, Lilly, Inflammation, Retinopathy, Social responsibility, Severe cognitive impairment, Juvenile idiopathic arthritis, National Medical Products Administration, Degenerative disease, Macrophage, Bamlanivimab, Infection, Quality of life, Psoriasis, Uveitis, Pharmaceutical industry, Vaccine, Science, Chinese

is jointly developed by Junshi Biosciences and Mabwell (Shanghai) Bioscience Co., Ltd.

Key Points: 
  • is jointly developed by Junshi Biosciences and Mabwell (Shanghai) Bioscience Co., Ltd.
  • In March 2022, its indications including rheumatoid arthritis, ankylosing spondylitis and psoriasis were approved by the NMPA.
  • Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China.
  • Junshi Biosciences has more than 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou).

Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Non-squamous Non-Small Cell Lung Cancer

Retrieved on: 
화요일, 9월 20, 2022
OS, World, Safety, Lancet, ALK, PD-L2, Society, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Patient, Hospital, Somatic mutation, Research, Death, EUA, COVID-19, HKEX, NSCLC, National Medical Products Administration, Program, Ligand, SSE, Microbiology, NMPA, Mortality, EGFR, Peking Union Medical College, Autoimmunity, Junshi, Risk, FDA, ASCO, Social responsibility, Severe acute respiratory syndrome coronavirus 2, Bamlanivimab/etesevimab, Medicine, Progression-free survival, GLOBE, Marketing, Platinum, HIV disease progression rates, Cancer, Development, Incidence, World Health Organization, American Society of Clinical Oncology, Lung cancer, Pemetrexed, Lung, HR, PD-L1, PD-1, Bamlanivimab, Lilly, PFS, Infection, Pharmaceutical industry, Chinese, Science

This is the sixth indication approved for toripalimab in China and will bring more treatment options to Chinese patients with advanced NSCLC.

Key Points: 
  • This is the sixth indication approved for toripalimab in China and will bring more treatment options to Chinese patients with advanced NSCLC.
  • Professor Jie Wang from the Cancer Hospital, Chinese Academy of Medical Sciences elaborated on toripalimabs performance in clinical trials.
  • In China, the number of lung cancer patients is massive and so is the demand for treatment.
  • Junshi Biosciences has more than 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc).

Junshi Biosciences Announces FDA Approval of Investigational New Drug Application for JS110 (XPO1 inhibitor)

Retrieved on: 
금요일, 8월 26, 2022
Bamlanivimab/etesevimab, COVID-19, Patient, EUA, Tablet, Safety, IND, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Microbiology, Death, XPO1, Autoimmunity, Infection, National Medical Products Administration, Blood, Food, NMPA, Lilly, Social responsibility, Severe acute respiratory syndrome coronavirus 2, GLOBE, Tumor suppressor gene, HKEX, FDA, Cancer, Marketing, Bamlanivimab, Growth, SSE, Pharmaceutical industry, Junshi, Science, Chinese

So far, 6 innovative drugs in Junshi Biosciences pipeline have obtained IND approval from the FDA, and with this newest addition, there are now 7.

Key Points: 
  • So far, 6 innovative drugs in Junshi Biosciences pipeline have obtained IND approval from the FDA, and with this newest addition, there are now 7.
  • Junshi Biosciences currently owns the world-wide exclusive production rights, licensed production rights and sales rights for JS110.
  • Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China.
  • Junshi Biosciences has more than 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc).

Junshi Biosciences Announces Acceptance of Supplemental Application for Additional Indications of Adalimumab Injection

Retrieved on: 
목요일, 8월 18, 2022
Psoriasis, GLOBE, Death, EUA, Prevalence, Marketing, Patient, Ulcerative colitis, Glaucoma, National Medical Products Administration, Inflammation, Junshi, IBD, Autoimmunity, Macular edema, Social responsibility, Lilly, B cell, HKEX, NMPA, Safety, SSE, Juvenile idiopathic arthritis, Rheumatoid arthritis, Incidence, Rheumatism, Microbiology, Cancer, COVID-19, Severe acute respiratory syndrome coronavirus 2, Degenerative disease, FDA, Inflammatory bowel disease, Retinopathy, Cataract, UC, Ankylosing spondylitis, Bamlanivimab, Multifocal choroiditis and panuveitis, Quality of life, Company, Infection, TNF, Severe cognitive impairment, Macrophage, Bamlanivimab/etesevimab, Uveitis, Pharmaceutical industry, Vaccine, Chinese, Science

SHANGHAI, China, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the Company has received an Acceptance Notice issued by the National Medical Products Administration (“NMPA”). The supplemental application for additional indications of the company’s adalimumab injection (project code: UBP1211, trade name: 君迈康), including the treatment of Crohn’s disease, uveitis, polyarticular juvenile idiopathic arthritis, plaque psoriasis in children and Crohn’s disease in children, has been accepted.

Key Points: 
  • The supplemental application for additional indications of the companys adalimumab injection (project code: UBP1211, trade name: ), including the treatment of Crohns disease, uveitis, polyarticular juvenile idiopathic arthritis, plaque psoriasis in children and Crohns disease in children, has been accepted.
  • is jointly developed by Junshi Biosciences and Mabwell (Shanghai) Bioscience Co., Ltd.
  • In March 2022, its indications including rheumatoid arthritis, ankylosing spondylitis and psoriasis were approved by the NMPA.
  • Junshi Biosciences has more than 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc).

La Jolla Institute for Immunology Acquires the Carterra LSA Platform to Advance State-of-the-Art Immunological and Infectious Disease Research

Retrieved on: 
월요일, 8월 1, 2022
Health, Medical Devices, Infectious Diseases, Research, Science, Pharmaceutical, Biotechnology, La Jolla Institute for Immunology, Antibody, Mab, Bamlanivimab, Čović, NIH, Time, Pandemic, Industry, NIAID, Research, Software, Cros, Institute, Health, Immune system, COVID-19, Multimedia, Bill & Melinda Gates Foundation, LSA, Eli Lilly, Technology, Disease, FDA, Method, Life, Microfluidics, Therapy, Autoimmunity, Sera, PerkinElmer, AbCellera, Vaccine, Pharmaceutical industry, Immunology, Science

It was through this collaboration that LJI discovered the power and magnitude of the LSAs capabilities.

Key Points: 
  • It was through this collaboration that LJI discovered the power and magnitude of the LSAs capabilities.
  • The LSA will also enable the rapid characterization of sera samples from vaccine studies, in addition to autoimmune and cancer targets.
  • Were proud to see the benefit of Carterras LSA platform being brought to bear for global good, says Tim Germann, Chief Commercial Officer at Carterra.
  • Since its founding in 1988 as an independent, nonprofit research organization, the Institute has made numerous advances leading toward its goal: life without disease.

Carterra Joins the Tetra Partner Network to Advance Therapeutics Discovery

Retrieved on: 
수요일, 7월 13, 2022
Cloud, Tetra, Technology, Movement, Microfluidics, Life, Antibody, SPR, Multimedia, Mab, R, ELN, PerkinElmer, TPN, LSA, CEO, COVID-19, Time, AI, Therapy, TDP, Data science, Eli Lilly, Cros, Software, Industry, Bamlanivimab, Medical device, Online shopping, Fine chemical

BOSTON, July 13, 2022 /PRNewswire/ -- TetraScience, the R&D Data Cloud company, announced today that Carterra, Inc., the world leader in label-free high throughput antibody screening and characterization, has joined the Tetra Partner Network (TPN) so that scientists can achieve greater velocity and scientific insights when analyzing the potential of antibodies as drug candidates.

Key Points: 
  • "TPN is thrilled to welcome Carterra to the TPN, whose LSA instrument and software platform are creating a new standard in antibody discovery," said Alan Millar, Ph.D., Vice President, TPN.
  • "We are delighted to partner with TetraScience to create additional value for our customers," said Tim Germann, Chief Commercial Officer, Carterra.
  • "In turn, AI and data science will uncover insights that will accelerate discovery and development of therapeutics that extend and enhance human life.
  • Carterra is privately held and is the leading provider of high-throughput technologies designed to accelerate and improve the discovery of novel therapeutic candidates.

Junshi Biosciences and Coherus Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma

Retrieved on: 
수요일, 7월 6, 2022
Patient, Nose, Biosimilar, GLOBE, Marketing, COVID-19, Biologics license application, Pharynx, PD-L2, Ranibizumab, Drug development, EUA, Primary tumor, Severe acute respiratory syndrome coronavirus 2, National Medical Products Administration, FDA, Bamlanivimab, Infection, Journal of Clinical Oncology, Skull, NMPA, Breakthrough therapy, Agency, Immunotherapy, Travel, Autoimmunity, SSE, CEO, Blas, NPC, Orphan drug, American Society of Clinical Oncology, Lilly, Nasopharyngeal carcinoma, Private Securities Litigation Reform Act, Social responsibility, HKEX, Review, Journal, Cisplatin, Bamlanivimab/etesevimab, Ligand, HIV disease progression rates, Nature Medicine, PD-1, U.S. Securities and Exchange Commission, United, PD-L1, Risk, Cancer, Radiation, PDUFA, Society, BLA, Medical device, Pharmaceutical industry, Science

SHANGHAI, China and REDWOOD CITY, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”) announced today that the United States Food and Drug Administration ("FDA") has accepted for review the Biologics License Application (“BLA”) resubmission for toripalimab in combination with gemcitabine and cisplatin as first-line treatment for patients with advanced recurrent or metastatic nasopharyngeal carcinoma (“NPC”) and for toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy.

Key Points: 
  • Over the next several months, we will work closely with the FDA to facilitate the review of this novel drug.
  • Toripalimab would address a critical unmet medical need for patients with nasopharyngeal carcinoma, an aggressive cancer for which there are currently no FDA-approved immunotherapy treatments.
  • We collaborated closely with our partner, Junshi Biosciences, to complete the quality process changes requested by the FDA and facilitate the rapid resubmission of the toripalimab BLA, said Dr. Theresa LaVallee, Chief Development Officer of Coherus.
  • The resubmission of the BLA for toripalimab for the treatment of NPC was accepted by the FDA in July 2022.